“The purpose of this seed funding is to provide additional support to faculty working on high-potential projects in life sciences for which we believe we can provide enabling resources to facilitate rapid commercialization.” Of particular interest to Hertig and the institute is the work of Eric Nauman, associate professor of mechanical engineering and biomedical engineering.Working closely with Darryl Dickerson, who recently earned his biomedical engineering Ph D, Nauman is creating tissue scaffold technology to improve damaged ligament and tendon reattachment to bone structures and provide a cartilage repair between bone interfaces for diseases such as osteoarthritis, which affects over 20 million Americans alone.And while this particular Hertig would take his mechanical engineering degree and have several startup entrepreneurial successes in the medical device industry, a happy coincidence brought him back to his alma mater two years ago.As the executive director of the Alfred Mann Institute for Biomedical Development at Purdue (AMIPurdue), Hertig is now helping to bring products from the labs to the forefront of the healthcare industry.
Spafford Listen in while four renowned security professionals chat about security.
Interestingly, his oldest son, another John Hertig, started in engineering at Purdue but ended up switching majors and getting his Pharm D instead.
Nevertheless, his youngest son, a “chip off the old block,” says his father, is pursuing his BSME.
“Our mission is to support the commercialization of life science technologies created at Purdue that help mankind,” he says.
“We feel these technologies that are emerging from the discovery stage have the potential to make a significant contribution toward improving healthcare.” The Alfred Mann Institute for Biomedical Development at Purdue was established in 2007 through a 0 million endowment from the California-based Alfred E. The institute works closely with Purdue’s Office of Technology Commercialization, part of the Purdue Research Foundation.